<DOC>
	<DOCNO>NCT02274155</DOCNO>
	<brief_summary>The purpose study test safety anti-OX40 antibody , MEDI6469 , give prior surgery patient advance head neck squamous cell carcinoma .</brief_summary>
	<brief_title>Anti-OX40 Antibody Head Neck Cancer Patients</brief_title>
	<detailed_description>This phase Ib clinical trial use MEDI6469 various dose interval prior definitive surgical resection patient stage III IV Oral Head Neck Squamous Cell Carcinoma ( OHNSCC ) primary objective determine safety feasibility preoperative MEDI6469 administration . In addition , tumor tissue peripheral blood obtain exploratory immunologic end point include measurement tumor infiltrate immune cell population base flow cytometry immunohistochemistry well circulate immunological parameter may correlate change induce MEDI6469 administration .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Patients treatment naive , resectable , stage III IV squamous cell carcinoma oral cavity , oropharynx , hypopharynx larynx candidate definitive surgical resection follow standard risk adapt adjuvant therapy . Histologic cytologic diagnosis primary OHNSCC radiological evidence metastatic disease acceptable . Patients bone cartilage invasion T N stage acceptable . Patients oral cavity primary manage use conventional transoral transcervical technique ; oropharynx hypopharynx tumor manage transoral robotic surgery ; larynx tumor ( T3/T4 thyroid cartilage invasion ) manage either total laryngectomy larynx preservation surgery . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Laboratory value ( perform within 28 day prior enrollment ) within protocol define range Ability give inform consent comply protocol . Patients history psychiatric illness must judge able understand investigational nature study risk associate therapy . No active gastrointestinal bleeding . Anticipated lifespan great 12 week . Locoregionally unresectable Metastatic disease ( stage IVB ) Active infection . Active autoimmune disease include patient Inflammatory Bowel Disease determine autoimmune questionnaire . Previous treatment mouse monoclonal antibody Need chronic maintenance oral steroid &gt; 5mg prednisone daily equivalent . Any medical psychiatric condition opinion investigator would preclude compliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>anti-OX40 antibody</keyword>
	<keyword>MEDI6469</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>